Sun Pharma to conduct clinical trial in COVID-19 patients
News

Sun Pharma to conduct clinical trial in COVID-19 patients

Newsdesk |
May 29, 2020

Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.


New Delhi, 29 May 2020

"Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany," the company said in a statement. As per news report of Reuters,  The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

Source -in.reuters.com


Read More >>


If you like the story and if you wish more such stories, support our effort Make a donation.




Loading...

If you believe investigative journalism is essential to making democracy functional and accountable support us. »